Sanofi: Alirocumab delivers on promises

BUY, Fair Value EUR94 (+14%)

News published on September Monday 1, 2014
Share on
Data disclosed at the ESC confirm efficacy of PCSK9 inhibitors on LDL-c over 52-78 weeks. A trend towards a cv mortality benefit is seen. Only neurognitive adverse events will have to be monitored.

For further information please contact marketing@bryangarnier.com


The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities